COVID-19: combining antiviral and anti-inflammatory treatments

The Lancet Infectious Diseases

Volumn 20, Issue 4, 2020, Pages 400-402

  Stebbing, Justin ^a   Phelan, Anne ^b   Griffin, Ivan ^b   Tucker, Catherine ^b   Oechsle, Olly ^b   Smith, Dan ^b   Richardson, Peter ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Benevolent AI   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AAK1 PROTEIN; ANTIINFLAMMATORY AGENT; ANTIVIRUS AGENT; BARICITINIB; CLATHRIN; CYTOCHROME P450; ERLOTINIB; FEDRATINIB; GAK PROTEIN; GAMMA INTERFERON; JANUS KINASE; LOPINAVIR; METHOTREXATE; PLACEBO; REMDESIVIR; RITONAVIR; RUXOLITINIB; SUNITINIB; TOFACITINIB; UNCLASSIFIED DRUG; AZETIDINE DERIVATIVE; SULFONAMIDE;

ALGORITHM; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ARTIFICIAL INTELLIGENCE; CHRONIC INFLAMMATION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; CORONAVIRUS DISEASE 2019; CORONAVIRUS INFECTION; DENGUE VIRUS; DRUG TARGETING; EBOLAVIRUS; ENDOCYTOSIS; ENZYME INHIBITION; EPIDEMIC; EUROPEAN MEDICINES AGENCY; HEPATITIS C VIRUS; HERPES ZOSTER; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INCIDENCE; JAK-STAT SIGNALING; LUNG INJURY; MYELOFIBROSIS; NOTE; PATHOGENESIS; PHARMACOKINETIC PARAMETERS; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; RHEUMATOID ARTHRITIS; SARS CORONAVIRUS; SARS CORONAVIRUS 2; SEVERE ACUTE RESPIRATORY SYNDROME; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; SIDE EFFECT; THERAPEUTIC DOSE; TREATMENT INDICATION; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS REPLICATION; BETACORONAVIRUS; PANDEMIC; VIRUS PNEUMONIA;

ANTI-INFLAMMATORY AGENTS; ANTIVIRAL AGENTS; AZETIDINES; BETACORONAVIRUS; CORONAVIRUS INFECTIONS; PANDEMICS; PNEUMONIA, VIRAL; SULFONAMIDES;

EID: 85082191760     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(20)30132-8     Document Type: Note

References (8)

1. Peiris, JSM, Chu, CM, Cheng, VCC, et al. Clinical progression and viral load in a community outbreak or coronavirus-associated SARS pneumonia: a prospective study. Lancet 361 (2003), 1767–1772.
2. Huang, C, Wang, Y, Li, X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395 (2020), 497–506 https://doi.org/10.1016/S0140-6736(20)30183-5.
3. Richardson, P, Griffin, I, Tucker, C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 395 (2020), 497–506.
4. Segler, MHS, Preuss, M, Waller, P, Planning chemical syntheses with deep neural networks and symbolic AI. Nature 555 (2018), 604–610.
5. Bekerman, E, Neveu, G, Shulla, A, et al. Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects. J Clin Invest 127 (2017), 1338–1352.
6. Pu, S-Y, Xiao, F, Schor, S, et al. Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment. Antiviral Res 155 (2018), 67–75.
7. European Medicines Agency. Olumiant: summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/olumiant-epar-product-information_en.pdf. (Accessed 24 February 2020)
8. Sanchez, GAM, Reinhardt, A, Ramsey, S, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest 128 (2018), 3041–3052.